Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Cancer. 2019 May 8;125(17):3013–3024. doi: 10.1002/cncr.32162

Figure 2.

Figure 2.

Kaplan Meier Estimates of A) Recurrence Free Survival (RFS) HR = 0.78 [95% CI: 0.64, 0.94] and B) Overall Survival (OS) HR = 0.88 [95% CI: 0.73, 1.07] for Patients Treated on E1684 and E1690 Based on the Pooled Analysis.